Surgical treatment of heart failure in China: towards the era of artificial heart.
10.3760/cma.j.cn112139-20220804-00340
- VernacularTitle:中国心力衰竭外科治疗进入人工心脏时代
- Author:
Sheng Shou HU
1
Author Information
1. National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Heart-Assist Devices;
Heart Failure/surgery*;
Heart, Artificial;
Heart Transplantation;
Pulsatile Flow
- From:
Chinese Journal of Surgery
2023;61(3):177-180
- CountryChina
- Language:Chinese
-
Abstract:
The number of patients with heart failure in China is large, and the proportion of patients with end-stage heart failure continues to increase. The clinical effect of guideline-directed medications therapy for end-stage heart failure is poor. Heart transplantation is the most effective treatment for end-stage heart failure. But it is faced with many limitations such as the shortage of donors. In recent years, the research and development of artificial heart in China has made great progress. Three devices have been approved by the National Medical Products Administration for marketing, and another one is undergoing pre-marketing clinical trial. Since 2017, more than 200 cases of ventricular assist device implantation have been carried out in more than 34 hospitals in China. Among them, 70 patients in Fuwai Hospital, Chinese Academy of Medical Sciences had a 2-year survival rate of 90%. The first patient has survived more than 5 years with the device. More efforts should be put into the training of standardized technical team and quality control. Further research should be carried out in the aspects of pulsatile blood flow pump, fully implanted cable-free device, and improved biomaterial with better blood compatibility.
